Pharmacology

• PO: 75 mg qday
• Mechanism: irreversibly inhibits platelet surface ADP receptor -> IIb/IIIa inhibition (IIb/IIIa normally acts as receptor for fibrinogen, vitronectin, fibronectin, and vWF) -> prevents cross-linking of platelets by fibrin -> inhibits platelet aggregation

Adverse Effects

• Diffuse Alveolar Hemorrhage (see Diffuse Alveolar Hemorrhage)
• Bleeding
• Neutropenia
• TTP
• Rash

References

• Diffuse Alveolar Hemorrhage After Clopidogrel Use. J Invasive Cardiol. 2001;13(7)